Download and explore these additional on-demand resources:
This slide deck provides a visual narrative of the role of phenotypic precision medicine in advanced prostate cancer.
This monograph offers a detailed review of the role of phenotypic precision medicine in advanced prostate cancer.
The front-and-back flash card displays a quick snapshot of the key points on how phenotypic biomarkers can simplify the approach to precision medicine in advanced prostate cancer.
Prostate Cancer Medical Expert Videos
The speakers in these videos have been compensated for their time by Advanced Accelerator Applications, a Novartis Company.
Why Is Precision Medicine Complicated in Advanced Prostate Cancer?
Ulka Vaishampayan, MBBS, FAB
Dr. Vaishampayan examines the challenges associated with traditional genotypic precision medicine that underscore the need for novel approaches to increase and simplify the use of precision medicine in advanced prostate cancer.
How Can Phenotypic Biomarkers Increase the Use of Precision Medicine in Advanced Prostate Cancer?
A. Oliver Sartor, MD
Dr. Sartor explores how phenotypic biomarkers, which can be detected through noninvasive diagnostics such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging, are emerging as a novel approach to facilitate decision making in advanced prostate cancer.
How Can PSMA Provide a Tailored Approach in Advanced Prostate Cancer?
Neal Shore, MD, FACS
Dr. Shore discusses the emerging role of PSMA as a diagnostic, prognostic, and potential therapeutic target, enabling a tailored approach to treating advanced prostate cancer. The overexpression of PSMA in >80% of patients with prostate cancer makes it an attractive target and a key phenotypic biomarker in advanced prostate cancer.
The Need for Novel Approaches to Precision Medicine in Advanced Prostate Cancer
Daniel J. George, MD
Dr. George evaluates the evolution of advanced prostate cancer management and the associated challenges of selecting and sequencing among available therapies. The current challenges of a genotypic precision medicine approach underlie the need for novel approaches that may simplify the use of precision medicine in advanced prostate cancer.
PSMA PET Imaging to Detect the Phenotypic Biomarker PSMA in Advanced Prostate Cancer
Phillip J. Koo, MD
Dr. Koo provides his clinical perspective on the changing imaging landscape in prostate cancer with a focus on the recent advancement of PET imaging radiotracers. Clinical studies with radiotracers based on PSMA have shown high specificity and sensitivity, demonstrating PSMA as a diagnostic tool for the detection of advanced prostate cancer.
Could PSMA Provide a Tailored Approach in Advanced Prostate Cancer?
Evan Y. Yu, MD
Dr. Yu describes the increased interest in the utility of PSMA as a key phenotypic biomarker in advanced prostate cancer. PSMA is emerging as a diagnostic and potential therapeutic target that may enable a phenotypic precision medicine approach to managing patients with advanced prostate cancer.